CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended		107 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
OPERATING EXPENSES
General and administrative	$ 277	$ 393	$ 711	$ 817	$ 32,197
Research and development	749	403	1,661	959	104,095
Purchased in-process research and development	0	0	0	0	34,311
Other	0	0	0	0	(375)
Total operating expenses	1,026	796	2,372	1,776	170,228
Interest and other income, net	3	(84)	(154)	(88)	(14,007)
Loss from continuing operations before taxes	1,029	712	2,218	1,688	156,221
Income tax benefit	(21)	0	(21)	0	(1,376)
Loss from continuing operations	1,008	712	2,197	1,688	154,845
Discontinued operations - net gain on sale of the bone device business, net of taxes of $267	0	0	0	0	(2,202)
NET LOSS	1,008	712	2,197	1,688	152,643
Less: Net Loss attributable to the noncontrolling interest	0	0	(193)	0	(667)
Net Loss attributable to Capstone Therapeutics Corp. stockholders	$ 1,008	$ 712	$ 2,004	$ 1,688	$ 151,976
Per Share Information:
Net loss, basic and diluted, attributable to Capstone Therapeutics Corp. stockholders (in dollars per share)	$ 0.02	$ 0.02	$ 0.05	$ 0.04
Basic and diluted shares outstanding (in shares)	40,885	40,878	40,885	40,875